What Evidence Exists for Cell-Based Treatments of Hip Osteoarthritis?
Published November 16, 2026
Protocol: 7 steps in this guide
The evidence is thin. A 2026 systematic review found nine studies with 307 patients, using several different cell products, in what it calls “predominantly uncontrolled designs.” The patients in those studies reported less pain and better function after treatment, but the authors stressed that these were within-group changes and that the small samples, mixed products, uncontrolled designs and limited safety reporting “preclude conclusions regarding efficacy or structural disease modification.” No cell product is FDA-approved for hip osteoarthritis, and the review’s conclusion leaves no basis for claiming that these injections delay or prevent hip replacement.
Hip osteoarthritis as its own diagnosis
Hip osteoarthritis is a different condition from knee osteoarthritis and from avascular necrosis of the hip, where bone loses its blood supply. Results from knee trials do not automatically apply to the hip. The 2026 VA/DoD guideline for non-surgical management of hip and knee osteoarthritis suggests against MRI, CT and ultrasound for diagnosing hip and knee osteoarthritis, so a clinic that bases a cell treatment on such imaging should be able to explain why. Cell-based treatment for the separate condition is covered in the evidence for cell-based treatment of avascular necrosis of the femoral head.
Which cell products were used
The 2026 review, by Steiner and colleagues in Wiener klinische Wochenschrift, Systematic evidence analysis of symptom modification in hip osteoarthritis following MSC-based interventions, included:
- culture-expanded mesenchymal stromal cells;
- bone marrow concentrate;
- stromal vascular fraction;
- micro-fragmented adipose tissue;
- any of these with or without platelet-rich plasma.
These are different products, made by different processes, and pooling them describes a field rather than one treatment. The products are explained in what mesenchymal stromal cells are, what bone marrow aspirate concentrate is and what stromal vascular fraction from adipose tissue is.
Nine studies, 307 patients
The review searched PubMed on August 1, 2024. One author performed screening, data extraction and risk-of-bias assessment, and because the studies differed so much, results were described rather than pooled into a single effect estimate. Averages were calculated only from studies that reported compatible values.
| Measure | Reported change | Number of patients contributing |
|---|---|---|
| VAS pain | 6.7 to 3.7 | 58 |
| WOMAC score | 35.4 to 18.5 | 49 |
| Harris hip score | 40.8 to 62.8 | 76 |
The review states: “These findings represent within-group changes rather than comparative treatment effects.” Each row draws on a subset of the 307 patients. The hip-specific HOOS questionnaire was not among the summary measures reported in the abstract.
Controlled versus uncontrolled designs
An improvement from before to after treatment can come from the injection, from natural changes in symptoms, from other care given at the same time, or from expectation. Only a control group, ideally with blinding, separates these. The review describes the hip evidence as “predominantly uncontrolled.” That is the main reason it does not establish that the injections work. Why this matters is explained in the difference between a placebo-controlled trial and an observational study.
Pain, function and walking
The scores above include pain and function measures; the Harris hip score covers function, including walking. The review describes within-group improvements of this size as encouraging, but without a comparison group they cannot show how much of the change came from the cells. The review also reports that serious adverse events “were uncommon, but reporting was incomplete and follow-up was generally limited.” How to judge whether a change matters to patients is covered in what clinically meaningful improvement means in a joint pain study.
Structural claims and imaging limits
The review concluded that the evidence does not support conclusions on “structural disease modification.” Claims that an injection regrows hip cartilage are therefore unsupported by this evidence. Knee MRI findings cannot be transferred to the hip; the broader question is covered in whether stem cell products can regrow damaged joint cartilage in humans. FDA’s patient and consumer information on regenerative medicine therapies lists “hip pain” among orthopedic conditions for which regenerative medicine therapies “have not been approved.”
Conservative care and what future research needs
For hip and knee osteoarthritis, the VA/DoD guideline suggests “a structured physical therapy program,” and its 2026 recommendation on stem cell injections, finding insufficient evidence to recommend for or against them, is written for osteoarthritis of the knee. For the hip, its injection recommendation on platelet-rich plasma also finds insufficient evidence, as covered in how effective PRP is for hip osteoarthritis according to clinical studies. The Steiner review concludes: “Adequately powered randomized controlled trials with standardized products and outcomes are required.” Until such trials report, a cell injection for hip osteoarthritis is best understood as experimental, ideally offered within a registered study.
Cell-based treatments for hip osteoarthritis rest on nine small, mostly uncontrolled studies showing within-group symptom improvements, which cannot establish that the injections work, rebuild cartilage or delay hip replacement, so they remain an experimental option rather than an established treatment.
Cells linked to this one
This guide leads on to
- F5 What Is the Evidence for Cell-Based Treatment of Avascular Necrosis of the Femoral Head?
- E2 What Are Mesenchymal Stromal Cells (MSCs)?
- E3 What Is Bone Marrow Aspirate Concentrate (BMAC)?
- E4 What Is Stromal Vascular Fraction (SVF) From Adipose Tissue?
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- I9 What Does Clinically Meaningful Improvement Mean in a Joint Pain Study?
- F3 Can Stem Cell Products Regrow Damaged Joint Cartilage in Humans?
- C7 How Effective Is PRP for Hip Osteoarthritis According to Clinical Studies?
Add a remark